SARS‐CoV‐2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment
Abstract The emergence of drug‐resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID‐19 pandemic. While de novo drug development is a time‐consuming process, repurposing existing approved medications...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley-VCH
2024-11-01
|
| Series: | ChemistryOpen |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/open.202400091 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846166840264359936 |
|---|---|
| author | B.Sc. Sara Protić M.Sc. Milica Crnoglavac Popović M.Sc. Nevena Kaličanin Dr. Olivera Prodanović Dr. Milan Senćanski Dr. Jelena Milićević Dr. Kristina Stevanović Dr. Vladimir Perović Dr. Slobodan Paessler Dr. Radivoje Prodanović Dr. Sanja Glišić |
| author_facet | B.Sc. Sara Protić M.Sc. Milica Crnoglavac Popović M.Sc. Nevena Kaličanin Dr. Olivera Prodanović Dr. Milan Senćanski Dr. Jelena Milićević Dr. Kristina Stevanović Dr. Vladimir Perović Dr. Slobodan Paessler Dr. Radivoje Prodanović Dr. Sanja Glišić |
| author_sort | B.Sc. Sara Protić |
| collection | DOAJ |
| description | Abstract The emergence of drug‐resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID‐19 pandemic. While de novo drug development is a time‐consuming process, repurposing existing approved medications offers a more expedient approach. In our prior in silico screening of the DrugBank database, fidaxomicin emerged as a potential SARS‐CoV‐2 papain‐like protease inhibitor. This study extends those findings by investigating fidaxomicin‘s antiviral properties in vitro. Our results support further exploration of fidaxomicin as a therapeutic candidate against SARS‐CoV‐2, given its promising in vitro antiviral activity and favorable safety profile. |
| format | Article |
| id | doaj-art-9fdc7793792c4bc5a3bb2984aed9eefb |
| institution | Kabale University |
| issn | 2191-1363 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wiley-VCH |
| record_format | Article |
| series | ChemistryOpen |
| spelling | doaj-art-9fdc7793792c4bc5a3bb2984aed9eefb2024-11-15T08:48:57ZengWiley-VCHChemistryOpen2191-13632024-11-011311n/an/a10.1002/open.202400091SARS‐CoV‐2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro AssessmentB.Sc. Sara Protić0M.Sc. Milica Crnoglavac Popović1M.Sc. Nevena Kaličanin2Dr. Olivera Prodanović3Dr. Milan Senćanski4Dr. Jelena Milićević5Dr. Kristina Stevanović6Dr. Vladimir Perović7Dr. Slobodan Paessler8Dr. Radivoje Prodanović9Dr. Sanja Glišić10Faculty of Chemistry University of Belgrade Studentski Trg 12–16 Belgrade SerbiaFaculty of Chemistry University of Belgrade Studentski Trg 12–16 Belgrade SerbiaInstitute of Chemistry Technology and Metallurgy University of Belgrade Njegoševa 12 Belgrade SerbiaInstitute for Multidisciplinary Research University of Belgrade Kneza Višeslava 1 Belgrade SerbiaLaboratory of Bioinformatics and Computational Chemistry Institute of Nuclear Sciences Vinca National Institute of the Republic of Serbia University of Belgrade Mike Petrovica Alasa 12–14 Belgrade SerbiaLaboratory of Bioinformatics and Computational Chemistry Institute of Nuclear Sciences Vinca National Institute of the Republic of Serbia University of Belgrade Mike Petrovica Alasa 12–14 Belgrade SerbiaLaboratory of Bioinformatics and Computational Chemistry Institute of Nuclear Sciences Vinca National Institute of the Republic of Serbia University of Belgrade Mike Petrovica Alasa 12–14 Belgrade SerbiaLaboratory of Bioinformatics and Computational Chemistry Institute of Nuclear Sciences Vinca National Institute of the Republic of Serbia University of Belgrade Mike Petrovica Alasa 12–14 Belgrade SerbiaDepartment of Pathology University of Texas Medical Branch Galveston Texas United StatesFaculty of Chemistry University of Belgrade Studentski Trg 12–16 Belgrade SerbiaLaboratory of Bioinformatics and Computational Chemistry Institute of Nuclear Sciences Vinca National Institute of the Republic of Serbia University of Belgrade Mike Petrovica Alasa 12–14 Belgrade SerbiaAbstract The emergence of drug‐resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID‐19 pandemic. While de novo drug development is a time‐consuming process, repurposing existing approved medications offers a more expedient approach. In our prior in silico screening of the DrugBank database, fidaxomicin emerged as a potential SARS‐CoV‐2 papain‐like protease inhibitor. This study extends those findings by investigating fidaxomicin‘s antiviral properties in vitro. Our results support further exploration of fidaxomicin as a therapeutic candidate against SARS‐CoV‐2, given its promising in vitro antiviral activity and favorable safety profile.https://doi.org/10.1002/open.202400091antiviral therapydrug repurposingfidaxomicinSARS-CoV-2 PLproin vitro |
| spellingShingle | B.Sc. Sara Protić M.Sc. Milica Crnoglavac Popović M.Sc. Nevena Kaličanin Dr. Olivera Prodanović Dr. Milan Senćanski Dr. Jelena Milićević Dr. Kristina Stevanović Dr. Vladimir Perović Dr. Slobodan Paessler Dr. Radivoje Prodanović Dr. Sanja Glišić SARS‐CoV‐2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment ChemistryOpen antiviral therapy drug repurposing fidaxomicin SARS-CoV-2 PLpro in vitro |
| title | SARS‐CoV‐2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment |
| title_full | SARS‐CoV‐2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment |
| title_fullStr | SARS‐CoV‐2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment |
| title_full_unstemmed | SARS‐CoV‐2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment |
| title_short | SARS‐CoV‐2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment |
| title_sort | sars cov 2 plpro inhibition evaluating in silico repurposed fidaxomicin s antiviral activity through in vitro assessment |
| topic | antiviral therapy drug repurposing fidaxomicin SARS-CoV-2 PLpro in vitro |
| url | https://doi.org/10.1002/open.202400091 |
| work_keys_str_mv | AT bscsaraprotic sarscov2plproinhibitionevaluatinginsilicorepurposedfidaxomicinsantiviralactivitythroughinvitroassessment AT mscmilicacrnoglavacpopovic sarscov2plproinhibitionevaluatinginsilicorepurposedfidaxomicinsantiviralactivitythroughinvitroassessment AT mscnevenakalicanin sarscov2plproinhibitionevaluatinginsilicorepurposedfidaxomicinsantiviralactivitythroughinvitroassessment AT droliveraprodanovic sarscov2plproinhibitionevaluatinginsilicorepurposedfidaxomicinsantiviralactivitythroughinvitroassessment AT drmilansencanski sarscov2plproinhibitionevaluatinginsilicorepurposedfidaxomicinsantiviralactivitythroughinvitroassessment AT drjelenamilicevic sarscov2plproinhibitionevaluatinginsilicorepurposedfidaxomicinsantiviralactivitythroughinvitroassessment AT drkristinastevanovic sarscov2plproinhibitionevaluatinginsilicorepurposedfidaxomicinsantiviralactivitythroughinvitroassessment AT drvladimirperovic sarscov2plproinhibitionevaluatinginsilicorepurposedfidaxomicinsantiviralactivitythroughinvitroassessment AT drslobodanpaessler sarscov2plproinhibitionevaluatinginsilicorepurposedfidaxomicinsantiviralactivitythroughinvitroassessment AT drradivojeprodanovic sarscov2plproinhibitionevaluatinginsilicorepurposedfidaxomicinsantiviralactivitythroughinvitroassessment AT drsanjaglisic sarscov2plproinhibitionevaluatinginsilicorepurposedfidaxomicinsantiviralactivitythroughinvitroassessment |